Partnership Aims to Enhance Early Phase Oncology Trials
The START Center for Cancer Research ("START") has announced an exciting strategic partnership with OneOncology that will create early phase clinical trial sites across key areas in the United States. This collaboration is set to launch three new START research sites in major cities, making cutting-edge clinical trials more accessible to patients. The network will include locations such as the Los Angeles Cancer Network, The Center for Cancer and Blood Disorders, and Astera Cancer Care. The initiative is a significant step forward in addressing the critical need for innovative cancer therapies among community practices where 80% of cancer patients are treated.
Addressing the Gap in Cancer Trial Accessibility
In the current landscape of cancer research, reliance on academic medical centers often limits access to essential trials. According to Nick Slack, Chairman and CEO of START, "The existing early phase cancer research infrastructure is no longer sustainable in light of increasing demands for rapid trial activation and the need for diversity in patient representation." By embedding trials within community settings, START aims to revolutionize cancer research and drug development, enhancing the patient experience and outcomes.
Focusing on Community Needs
The partnership with OneOncology allows community practices, like those involved in this initiative, to extend their services into innovative early phase research. Jeff Patton, MD, CEO of OneOncology, explained, "Our mission is to elevate community oncology care. Collaborating with START provides our practices with significant research capabilities, allowing patients access to therapies previously reserved for academic institutions." This shift will streamline drug development processes and cultivate healthier patient pathways.
A Proven Track Record of Successful Trials
START is well recognized as the world's largest early phase oncology research network, with ten clinical trial sites overseeing over 700 early phase trials. They have played a pivotal role in the development of more than 45 novel cancer therapies that have received FDA and EMA approval. By collaborating with OneOncology, START is poised to further enhance its outreach and impact in the oncology landscape.
Benefits for Patients Across the Nation
The expansion into key communities will offer patients timely access to groundbreaking clinical trials. Leaders of the collaborative practices express unwavering enthusiasm for this innovative initiative. Troy Simon, CEO of the Los Angeles Cancer Network, remarked on the transformative potential of this partnership, highlighting its dedication to providing patients with advanced treatment options. Barry Russo, CEO of The Center for Cancer and Blood Disorders, further emphasized the enhancements to patient care that this collaboration provides.
Future Directions for START and OneOncology
Set to begin in July 2025 and continue through early 2026, the expansion of START sites will align with OneOncology’s operational frameworks, ensuring seamless integration and efficient trial execution. This collaboration not only bridges the innovation gap between community and academic oncology but also assures patients in underserved areas have access to transformative research.
About START
START, known for its strong roots in community oncology, specializes in providing access to advanced preclinical and early phase clinical trials for new cancer treatments. With its extensive network of sites and Principal Investigators, START has been an influential force in developing therapies that have greatly improved patient outcomes. The organization remains committed to accelerating patient access to innovative treatments.
About OneOncology
Founded by community oncologists, OneOncology focuses on improving the lives of patients facing cancer. With a network of over 1,750 providers distributed across more than 565 practices nationally, OneOncology aims to enhance community care while ensuring accessibility and quality. This partnership with START is another step in fulfilling its mission to make groundbreaking oncology care available in local communities.
Frequently Asked Questions
What is the main goal of the START and OneOncology partnership?
The primary goal is to expand access to early phase clinical trials for cancer patients within community practices, making innovative therapies more widely available.
Where will the new START research sites be located?
New START research sites will be established in Los Angeles, Texas, and New Jersey as part of this collaboration.
How does this partnership benefit cancer patients?
Patients will gain timely access to advanced clinical trials and treatment options that were previously exclusive to academic centers, enhancing their overall care experience.
What has been START's impact on cancer research?
START has contributed to the development of over 45 approved cancer therapies and oversees numerous early phase clinical trials globally, solidifying its role as a leader in oncology research.
When will the expansion of START sites commence?
The expansion is set to begin in July 2025, with activations continuing into early 2026 as practices integrate into START's operational framework.
